# Beyfortus (nirsevimab-alip) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/nirsevimab-alip

> The FDA approved Beyfortus (nirsevimab-alip), sponsored by ASTRAZENECA PLC (AZN), on July 17, 2023 for to prevent respiratory syncytial virus (RSV) lower respiratory tract diseasePress Release.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Beyfortus (nirsevimab-alip) FDA approved?

Yes. The FDA approved Beyfortus (nirsevimab-alip), sponsored by ASTRAZENECA PLC (AZN), on July 17, 2023 for to prevent respiratory syncytial virus (RSV) lower respiratory tract diseasePress Release. FDA novel drug approvals: "Beyfortus | nirsevimab-alip | 7/17/2023 | To prevent respiratory syncytial virus (RSV) lower respiratory tract diseasePress ReleaseDrug Trials Snapshot" [Calendar and source filings](https://sec-api.dev/pdufa/nirsevimab-alip)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/nirsevimab-alip#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Beyfortus (nirsevimab-alip) |
| Codes |  |
| Sponsor | ASTRAZENECA PLC (AZN) https://sec-api.dev/companies/azn/catalysts |
| Indications | To prevent respiratory syncytial virus (RSV) lower respiratory tract diseasePress Release |
| Modality | biologic |
| FDA designations | none disclosed |

## Timeline

### June 8, 2023: FDA advisory committee meeting

- Status: completed, positive. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA advisory committee calendar: "The committee will discuss biologics license application (BLA) 761328, for nirsevimab, a long-acting respiratory syncytial virus (RSV) F protein inhibitor monoclonal antibody for intramuscular use, submitted by AstraZeneca AB. The proposed indication is prevention of RSV lower respiratory tract disease in: Neonates and infants born during or entering their first RSV season." https://www.fda.gov/advisory-committees/advisory-committee-calendar/june-8-2023-meeting-antimicrobial-drugs-advisory-committee-meeting-announcement-06082023
- FDA advisory committee calendar: "VOTE: Is the overall benefit-risk assessment favorable for the use of nirsevimab for the prevention of respiratory syncytial virus (RSV) lower respiratory disease in neonates and infants born during or entering their first RSV season? a. If yes, please discuss your rationale. b. If no, please comment on what additional clinical data are needed to support this indication. Vote Result: Yes: 21 No: 0 Abstain: 0" https://www.fda.gov/media/170807/download
- FDA advisory committee calendar: "VOTE: Is the overall benefit-risk assessment favorable for the use of nirsevimab for the prevention of RSV lower respiratory tract disease in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season? a. If yes, please discuss your rationale. Page 5 of 6 June 8, 2023 Antimicrobial Drugs Advisory Committee Meeting b. If no, please comment on what additional clinical data are needed to support this indication. Vote Result: Yes: 19 No: 2 Abstain: 0" https://www.fda.gov/media/170807/download

### July 17, 2023: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To prevent respiratory syncytial virus (RSV) lower respiratory tract diseasePress Release.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Beyfortus | nirsevimab-alip | 7/17/2023 | To prevent respiratory syncytial virus (RSV) lower respiratory tract diseasePress ReleaseDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023
- openFDA Drugs@FDA: "BLA761328 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20230717, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product BEYFORTUS (NIRSEVIMAB-ALIP)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761328%22

### August 22, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761328 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20240822, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product BEYFORTUS (NIRSEVIMAB-ALIP)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761328%22

### October 20, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761328 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20251020, review_priority STANDARD; sponsor_name ASTRAZENECA AB; product BEYFORTUS (NIRSEVIMAB-ALIP)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761328%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/nirsevimab-alip.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Beyfortus (nirsevimab-alip) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/nirsevimab-alip

```bibtex
@misc{secapidev_pdufa_nirsevimab_alip_20261116,
  title        = {Beyfortus (nirsevimab-alip) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/nirsevimab-alip}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_nirsevimab_alip_20261116","title":"Beyfortus (nirsevimab-alip) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/nirsevimab-alip","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
